左卡尼汀联合美托洛尔治疗儿童扩张型心肌病的效果及对血清s ST2、TGF-β及心功能的影响

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (2133 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect of levocarnitine combined with metoprolol in the treatment of children with dilated cardiomyopathy, as well as the influence on serum soluble ST2 protein (s ST2), transforming growth factor (TGF) and cardiac function-related indicators. Methods From January 2019 to November 2022, 22 children with Dilated cardiomyopathy admitted to Yulin Red Cross Society Hospital and 70 children with Dilated cardiomyopathy admitted to West China Second Hospital of Sichuan University were selected as research subjects, and divided into experimental group (n=47) and control group (n=45) by the random number table approach. Metoprolol was administered to the control group, while levocarnitine and metoprolol were administered to the experimental group. The clinical efficacy, vital signs, serum s ST2, TGF-β, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), adverse reactions were compared between the two groups. Results After 4 weeks of treatment, the total effective rate of treatment in experimental group was higher than that in control group (89.36% vs 71.11%). After treatment, the systolic blood pressure and diastolic blood pressure with (114.87±7.16) mmHg and (86.12±5.02) mmHg in experimental group were higher than (110.72±8.04) mmHg and (83.46±5.35) mmHg in control group while the heart rate with (100.34±9.24) beats/min was lower than (105.59±10.63) beats/min in control group. The levels of serum s ST2 and TGF-β in experimental group after treatment were (0.07±0.01) ng/mL and (131.12±10.07) ng/L, which were lower than (0.16±0.04) ng/mL and (185.46±7.41) ng/L in control group. After treatment, the LVESD and LVEDD with (30.71±7.12) mm and (63.28±9.18) mm in experimental group were lower than (36.89±6.56) mm and (70.79±10.56) mm in control group while the LVEF with (49.63±3.35) % was higher compared with (43.29±2.51) % in control group. After treatment, the 6 minutes walking distance with (399.64±59.97) m in experimental group was longer than (309.64±48.79) m in control group, and NT-proBNP with (2411.08±1108.15) ng/L was lower than (3451.14±1567.59) ng/L in control group. There was no significant difference in the incidence of adverse drug reactions. Conclusion Levocarnitine combined with metoprolol has a significant effect on children with dilated cardiomyopathy, and it can effectively improve the vital signs, serum s ST2, TGF-β and cardiac function, without increasing adverse reactions.

Key words： levocarnitine metoprolol children dilated cardiomyopathy soluble ST2 protein transforming growth factor-β cardiac function

Received: 11 April 2023

PACS:

R725.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIN Yi
	PENG Jie
	WANG Tao

Cite this article:

QIN Yi,PENG Jie,WANG Tao. Effectiveness of levocanidine in combination with metoprolol in the treatment of dilated cardiomyopathy in children and the effect on serum s ST2, TGF-β and cardiac function[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 88-91.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I3/88

[1] 王丹, 钟家蓉, 张静. 脑型利钠肽评估儿童扩张型心肌病急性失代偿性心力衰竭及心室重构的临床价值[J]. 儿科药学杂志, 2018, 24(08): 15-18.
[2] 朱庆, 赵艳丽, 韩丽媛, 等. 扩张型心肌病心肌纤维化与β-链蛋白表达相关性的初步分析[J]. 心肺血管病杂志, 2020, 39(04): 93-97.
[3] 李平, 李相俊, 成小凤, 等. 地高辛联合左西孟旦治疗扩张型心肌病的疗效及对血清HMGB1, sICAM-1, sST2水平的影响[J]. 现代生物医学进展, 2019, 19(19): 67-70.
[4] 张家立, 刘瑞浩, 陶阳. 左卡尼汀对治疗扩张型心肌病并发心力衰竭患者的影响[J]. 中国冶金工业医学杂志, 2022, 39(1): 67-68.
[5] 张娟, 王吉利, 谭月桂. 曲美他嗪联合美托洛尔治疗老年扩张型心肌病合并心力衰竭患者的临床疗效[J]. 河北医药, 2019, 41(05): 89-91+95.
[6] 中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(05): 421-434.
[7] 张仪, 李小梅, 江河, 等. 经导管消融儿童心室预激性扩张型心肌病临床及预后因素分析[J]. 中华心血管病杂志, 2019, 47(11): 901-906.
[8] Puyol-Anton E, Ruijsink B, Gerber B, et al.Regional Multi-View Learning for Cardiac Motion Analysis: Application to Identification of Dilated Cardiomyopathy Patients[J]. IEEE Trans Biomed Eng, 2019, 66(4): 956-966.
[9] 李江, 刘文娴, 赵晗, 等. 沙库巴曲缬沙坦治疗老年人扩张型心肌病致慢性心力衰竭的疗效观察[J]. 中国医药, 2019, 14(04): 14-17.
[10] 袁小媚, 王文艳, 伍鑫, 等. 间断重复静脉应用左西孟旦治疗老年扩张型心肌病患者的有效性研究[J]. 中华老年心脑血管病杂志, 2018, 20(08): 41-44.
[11] 朱耀文, 张华巍, 孙志军. 伊伐布雷定联合美托洛尔对缺血性心肌病患者PCI术后心功能的影响[J]. 解放军医学院学报, 2019, 40(03): 29-32+76.
[12] 张天耀. 左卡尼汀联合美托洛尔治疗缺血性心肌病心力衰竭的临床研究[J]. 中西医结合心脑血管病杂志, 2018, 16(11): 1537-1540.
[13] 冯莉莉, 王朝华, 李贺, 等. 扩张型心肌病血清miR-210、β2-MG及TGF-β1水平的表达及其临床意义[J]. 现代生物医学进展, 2022, 22(4): 688-692+717.
[14] 李玉, 段敬柱, 王崇全. 扩张型心肌病患者血清可溶性ST2与心室重构的相关性研究[J]. 解放军医药杂志, 2018, 217(07): 45-48.
[15] 杨胜祥, 雷玉华. 左卡尼汀治疗儿童扩张型心肌病的疗效观察[J]. 临床与病理杂志, 2019, 39(6): 1250-1254.